Literature DB >> 23500188

Differential development of tolerance to the functional and behavioral effects of repeated baclofen treatment in rats.

T J R Beveridge1, H R Smith, L J Porrino.   

Abstract

Baclofen, a gamma-aminobutyric acid (GABA)B receptor agonist, has been used clinically to treat muscle spasticity, rigidity and pain. More recently, interest in the use of baclofen as an addiction medicine has grown, with promising preclinical cocaine and amphetamine data and demonstrated clinical benefit from alcohol and nicotine studies. Few preclinical investigations, however, have utilized chronic dosing of baclofen, which is important given that tolerance can occur to many of its effects. Thus the question of whether chronic treatment of baclofen maintains the efficacy of acute doses is imperative. The neural substrates that underlie the effects of baclofen, particularly those after chronic treatment, are also not known. In the present study, therefore, rats were treated with either a) vehicle, b) acute baclofen (5 mg/kg) or c) chronic baclofen (5 mg/kg, t.i.d. for 5 days). The effects of acute and chronic baclofen administration, compared to vehicle, were assessed using locomotor activity and changes in brain glucose metabolism (a measure of functional brain activity). Acute baclofen significantly reduced locomotor activity (horizontal and total distance traveled), while chronic baclofen failed to affect locomotor activity. Acute baclofen resulted in significantly lower rates of local cerebral glucose utilization throughout many areas of the brain, including the prefrontal cortex, caudate putamen, septum and hippocampus. The majority of these functional effects, with the exception of the caudate putamen and septum, were absent in animals chronically treated with baclofen. Despite the tolerance to the locomotor and functional effects of baclofen following repeated treatment, these persistent effects on functional activity in the caudate putamen and septum may provide insights into the way in which baclofen alters the reinforcing effects of abused substances such as cocaine, alcohol, and methamphetamine both in humans and animal models.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23500188      PMCID: PMC3717556          DOI: 10.1016/j.pbb.2013.03.001

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  59 in total

1.  The subcellular localization of GABA(B) receptor subunits in the rat substantia nigra.

Authors:  Justin Boyes; J Paul Bolam
Journal:  Eur J Neurosci       Date:  2003-12       Impact factor: 3.386

2.  Phosphorylation and chronic agonist treatment atypically modulate GABAB receptor cell surface stability.

Authors:  Benjamin P Fairfax; Julie A Pitcher; Mark G H Scott; Andrew R Calver; Menelas N Pangalos; Stephen J Moss; Andrés Couve
Journal:  J Biol Chem       Date:  2004-01-05       Impact factor: 5.157

3.  Treatment of spasticity in a spinal cord-injured patient with intrathecal morphine due to intrathecal baclofen tolerance--a case report and review of literature.

Authors:  B M Soni; R M Mani; T Oo; S Vaidyanathan
Journal:  Spinal Cord       Date:  2003-10       Impact factor: 2.772

Review 4.  Intrathecal baclofen in pain management.

Authors:  Marc Slonimski; Stephen E Abram; Robert E Zuniga
Journal:  Reg Anesth Pain Med       Date:  2004 May-Jun       Impact factor: 6.288

Review 5.  GABA, gamma-hydroxybutyric acid, and neurological disease.

Authors:  C Guin Ting Wong; Teodoro Bottiglieri; O Carter Snead
Journal:  Ann Neurol       Date:  2003       Impact factor: 10.422

6.  Relationship between the antinociceptive response to desipramine and changes in GABAB receptor function and subunit expression in the dorsal horn of the rat spinal cord.

Authors:  Scott A Sands; Kenneth E McCarson; S J Enna
Journal:  Biochem Pharmacol       Date:  2004-02-15       Impact factor: 5.858

7.  Stereospecific actions of baclofen on sociosexual behavior, locomotor activity and motor execution.

Authors:  R Paredes; A Agmo
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

8.  Functional consequences of the repeated administration of Delta9-tetrahydrocannabinol in the rat.

Authors:  Christopher T Whitlow; Cory S Freedland; Linda J Porrino
Journal:  Drug Alcohol Depend       Date:  2003-08-20       Impact factor: 4.492

9.  Cloning and characterization of a rat brain receptor that binds the endogenous neuromodulator gamma-hydroxybutyrate (GHB).

Authors:  Christian Andriamampandry; Omar Taleb; Sandrine Viry; Claude Muller; Jean Paul Humbert; Serge Gobaille; Dominique Aunis; Michel Maitre
Journal:  FASEB J       Date:  2003-07-18       Impact factor: 5.191

10.  The γ-aminobutyric acid type B (GABAB) receptor agonist baclofen inhibits morphine sensitization by decreasing the dopamine level in rat nucleus accumbens.

Authors:  Zhenyu Fu; Hongfa Yang; Yuqiang Xiao; Gang Zhao; Haiyan Huang
Journal:  Behav Brain Funct       Date:  2012-07-10       Impact factor: 3.759

View more
  7 in total

1.  Chronic baclofen desensitizes GABA(B)-mediated G-protein activation and stimulates phosphorylation of kinases in mesocorticolimbic rat brain.

Authors:  Bradley M T Keegan; Thomas J R Beveridge; Jeffrey J Pezor; Ruoyu Xiao; Tammy Sexton; Steven R Childers; Allyn C Howlett
Journal:  Neuropharmacology       Date:  2015-02-25       Impact factor: 5.250

2.  Efficacy and side effects of baclofen and the novel GABAB receptor positive allosteric modulator CMPPE in animal models for alcohol and cocaine addiction.

Authors:  Valentina Vengeliene; Tatiane T Takahashi; Olga A Dravolina; Irina Belozertseva; Edwin Zvartau; Anton Y Bespalov; Rainer Spanagel
Journal:  Psychopharmacology (Berl)       Date:  2018-04-12       Impact factor: 4.530

3.  Acute and chronic alcohol administration: effects on performance of zebrafish in a latent learning task.

Authors:  Ana C Luchiari; Diana C Salajan; Robert Gerlai
Journal:  Behav Brain Res       Date:  2014-12-31       Impact factor: 3.332

4.  KK-92A, a novel GABAB receptor positive allosteric modulator, attenuates nicotine self-administration and cue-induced nicotine seeking in rats.

Authors:  Xia Li; Emmanuel Sturchler; Katarzyna Kaczanowska; Michael Cameron; M G Finn; Patrick Griffin; Patricia McDonald; Athina Markou
Journal:  Psychopharmacology (Berl)       Date:  2017-04-05       Impact factor: 4.530

5.  Effects of acute administration of the GABA(B) receptor agonist baclofen on behavioral flexibility in rats.

Authors:  B Sofia Beas; Barry Setlow; Jennifer L Bizon
Journal:  Psychopharmacology (Berl)       Date:  2016-06-02       Impact factor: 4.530

6.  Encephalopathy and hypotonia due to baclofen toxicity in a patient with end-stage renal disease.

Authors:  Mohsin Ijaz; Hassan Tariq; Muhammad Kashif; Jose Gomez Marquez
Journal:  Am J Case Rep       Date:  2015-04-20

Review 7.  A Review of the Potential Mechanisms of Action of Baclofen in Alcohol Use Disorder.

Authors:  Renaud de Beaurepaire
Journal:  Front Psychiatry       Date:  2018-10-17       Impact factor: 4.157

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.